Alzamend Neuro, Inc. SEC filings ALZN
Alzamend Neuro, Inc. has 397 filings in SEC EDGAR's recent list, going back to Jun 22, 2016. Its latest annual report, Form 10-K, was filed on Jul 22, 2026 for the period ended Apr 30, 2026. The latest quarterly report (Form 10-Q) was filed on Sep 10, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (regulation fd disclosure). The company's fiscal year ends on April 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| RW | Filing | Oct 9, 2026 | — |
| EFFECT | Filing | Apr 8, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2025 | — |
| NT 10-K | Filing | Jul 30, 2024 | Apr 30, 2024 |
| EFFECT | Filing | Jul 9, 2024 | — |
| CORRESP | Letter to the SEC | Jul 8, 2024 | — |
| CORRESP | Letter to the SEC | Jul 3, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2024 | — |
| CORRESP | Letter to the SEC | Jun 26, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2024 | — |
| NT 10-Q | Filing | Mar 18, 2024 | Jan 31, 2024 |
| EFFECT | Filing | Aug 10, 2023 | — |
| CORRESP | Letter to the SEC | Aug 8, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2023 | — |
| CORRESP | Letter to the SEC | Jun 15, 2021 | — |
| EFFECT | Filing | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| CERT | Filing | Jun 14, 2021 | — |
| 8-A12B | Filing | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 10, 2021 | — |
| CORRESP | Letter to the SEC | Jun 10, 2021 | — |
| CORRESP | Letter to the SEC | Jun 10, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| CORRESP | Letter to the SEC | Jun 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| CORRESP | Letter to the SEC | Jun 3, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2021 | — |
| CORRESP | Letter to the SEC | May 28, 2021 | — |
| CORRESP | Letter to the SEC | May 27, 2021 | — |
| CORRESP | Letter to the SEC | May 25, 2021 | — |
| UPLOAD | Letter from the SEC | May 20, 2021 | — |
| CORRESP | Letter to the SEC | May 10, 2021 | — |
| 1-U/A | Amendment no. 1 | May 7, 2021 | Mar 12, 2021 |
| UPLOAD | Letter from the SEC | Apr 20, 2021 | — |
| DRSLTR | Filing | Apr 2, 2021 | — |
| DRS/A | Filing | Apr 2, 2021 | — |
| 1-U | Filing | Mar 12, 2021 | Mar 12, 2021 |
| UPLOAD | Letter from the SEC | Jan 25, 2021 | — |
| 1-SA | Filing | Dec 29, 2020 | Oct 31, 2020 |
| DRSLTR | Filing | Dec 29, 2020 | — |
| DRS | Filing | Dec 29, 2020 | — |
| 1-U | Filing | Nov 17, 2020 | Nov 17, 2020 |
| 1-U | Filing | Nov 4, 2020 | Nov 1, 2020 |
| 1-A-W | Filing | Sep 21, 2020 | — |
| 1-K | Filing | Aug 28, 2020 | Apr 30, 2020 |
| 1-SA/A | Amendment no. 1 | Aug 28, 2020 | Oct 31, 2019 |
| 1-A/A | Filing | Mar 12, 2020 | — |
| 1-A/A | Filing | Feb 4, 2020 | — |
| 1-SA | Filing | Jan 29, 2020 | Oct 31, 2019 |
| 1-A | Filing | Nov 29, 2019 | — |
| 1-K | Filing | Aug 28, 2019 | Apr 30, 2019 |
| D | Filing | Apr 23, 2019 | — |
| 1-SA | Filing | Mar 1, 2019 | Oct 31, 2018 |
| 1-U | Filing | Feb 25, 2019 | Feb 25, 2019 |
| 1-K | Filing | Feb 21, 2019 | Apr 30, 2018 |
| 1-U | Filing | Jan 23, 2019 | Jan 22, 2019 |
| 1-U | Filing | Jan 14, 2019 | Nov 18, 2018 |
| 1-U | Filing | Jan 7, 2019 | Jan 7, 2019 |
| 1-U | Filing | Jul 2, 2018 | Jun 28, 2018 |
| 1-SA | Filing | Jan 30, 2018 | Oct 31, 2017 |
| 1-K | Filing | Jan 29, 2018 | Apr 30, 2017 |
| D | Filing | Aug 22, 2017 | — |
| 1-U | Filing | Jul 25, 2017 | Jul 19, 2017 |
| 1-SA | Filing | Jan 25, 2017 | Oct 31, 2016 |
| QUALIF | Filing | Dec 8, 2016 | — |
| CORRESP | Letter to the SEC | Dec 6, 2016 | — |
| 1-A/A | Filing | Nov 30, 2016 | — |
| 1-A | Filing | Nov 14, 2016 | — |
| DOSLTR | Filing | Oct 27, 2016 | — |
| DOS/A | Filing | Oct 27, 2016 | — |
| CORRESP | Letter to the SEC | Oct 20, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 6, 2016 | — |
| DOSLTR | Filing | Sep 29, 2016 | — |
| DOS/A | Filing | Sep 29, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 15, 2016 | — |
| DOS | Filing | Aug 19, 2016 | — |
| D | Filing | Jun 22, 2016 | — |
Showing 79 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.